Received Mar 3, 2025
| Type | Name | Manufacturer | Dose | Lot | Route / Site |
|---|---|---|---|---|---|
| MNQ | MENINGOCOCCAL CONJUGATE (MENVEO) | NOVARTIS VACCINES AND DIAGNOSTICS | UNK | AMVB056A | IM |
Inappropriate reconstitution technique; received only the liquid conjugate; This non-serious case was reported by a nurse and described the occurrence of inappropriate preparation of medication in a 11-year-old male patient who received Men ACWY-CRM NVS (Menveo) (batch number AMVB056A, expiry date 31-AUG-2025) for prophylaxis. On 20-FEB-2025, the patient received Menveo (intramuscular) .5 ml. On 20-FEB-2025, an unknown time after receiving Menveo, the patient experienced inappropriate preparation of medication (Verbatim: Inappropriate reconstitution technique) and inappropriate dose of vaccine administered (Verbatim: received only the liquid conjugate). On 20-FEB-2025, the outcome of the inappropriate preparation of medication was not applicable. The outcome of the inappropriate dose of vaccine administered was not applicable. Additional Information: GSK Receipt Date: 20-FEB-2025 The patient received only the liquid conjugate component of Menveo, and the liquid conjugate vial was not combined with the lyophilized conjugate component of Menveo, which led inappropriate preparation of medication and inappropriate dose of vaccine administered. The location of administration of the vaccine was unknown.